128 related articles for article (PubMed ID: 36796479)
1. Designing a Value-Based Formulary for a Commercial Health Plan: A Simulated Case Study of Diabetes Medications.
Chen Y; Loucks AR; Sullivan SD; Pearson SD; Kent D; Yeung K
Value Health; 2023 Jul; 26(7):1022-1031. PubMed ID: 36796479
[TBL] [Abstract][Full Text] [Related]
2. Drug use and spending under a formulary informed by cost-effectiveness.
Yeung K; Cruz M; Tsiao E; Watkins JB; Sullivan SD
J Manag Care Spec Pharm; 2023 Nov; 29(11):1175-1183. PubMed ID: 37889867
[No Abstract] [Full Text] [Related]
3. Impact of a value-based formulary in three chronic disease cohorts.
Yeung K; Basu A; Marcum ZA; Watkins JB; Sullivan SD
Am J Manag Care; 2017 Mar; 23(3 Suppl):S46-S53. PubMed ID: 29648740
[TBL] [Abstract][Full Text] [Related]
4. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
[TBL] [Abstract][Full Text] [Related]
5. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
6. The effect of a three-tier formulary on antidepressant utilization and expenditures.
Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
[TBL] [Abstract][Full Text] [Related]
7. Design, implementation, and first-year outcomes of a value-based drug formulary.
Sullivan SD; Yeung K; Vogeler C; Ramsey SD; Wong E; Murphy CO; Danielson D; Veenstra DL; Garrison LP; Burke W; Watkins JB
J Manag Care Spec Pharm; 2015 Apr; 21(4):269-75. PubMed ID: 25803760
[TBL] [Abstract][Full Text] [Related]
8. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
9. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
10. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
11. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
[TBL] [Abstract][Full Text] [Related]
12. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
Brouwer ED; Basu A; Yeung K
Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
[TBL] [Abstract][Full Text] [Related]
13. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
14. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
Hung A; Mullins CD; Slejko JF; Haines ST; Shaya F; Lugo A
J Manag Care Spec Pharm; 2019 Mar; 25(3):342-349. PubMed ID: 30816818
[TBL] [Abstract][Full Text] [Related]
15. Cost sharing for antiepileptic drugs: medication utilization and health plan costs.
Joyce NR; Fishman J; Green S; Labiner DM; Wild I; Grabowski DC
Am J Manag Care; 2018 Jun; 24(6):e183-e189. PubMed ID: 29939508
[TBL] [Abstract][Full Text] [Related]
16. Novel Type 2 Diabetes Medication Access and Effect of Patient Cost Sharing.
Henk HJ; Lopez JMS; Bookhart BK
J Manag Care Spec Pharm; 2018 Sep; 24(9):847-855. PubMed ID: 30156451
[TBL] [Abstract][Full Text] [Related]
17. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
[TBL] [Abstract][Full Text] [Related]
18. Does increased adherence to medications change health care financial burdens for adults with diabetes?
Miller GE; Sarpong EM; Hill SC
J Diabetes; 2015 Nov; 7(6):872-80. PubMed ID: 25817601
[TBL] [Abstract][Full Text] [Related]
19. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
[TBL] [Abstract][Full Text] [Related]
20. The effect of incentive-based formularies on prescription-drug utilization and spending.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
